BR112019024851A2 - agente para evitar ou tratar atrofia cerebral - Google Patents

agente para evitar ou tratar atrofia cerebral Download PDF

Info

Publication number
BR112019024851A2
BR112019024851A2 BR112019024851A BR112019024851A BR112019024851A2 BR 112019024851 A2 BR112019024851 A2 BR 112019024851A2 BR 112019024851 A BR112019024851 A BR 112019024851A BR 112019024851 A BR112019024851 A BR 112019024851A BR 112019024851 A2 BR112019024851 A2 BR 112019024851A2
Authority
BR
Brazil
Prior art keywords
cerebral atrophy
agent
prevent
treat cerebral
benzothiophen
Prior art date
Application number
BR112019024851A
Other languages
English (en)
Inventor
Kobayashi Hiroshi
Matsumoto Yoshihiko
Original Assignee
Fujifilm Toyama Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujifilm Toyama Chemical Co Ltd filed Critical Fujifilm Toyama Chemical Co Ltd
Publication of BR112019024851A2 publication Critical patent/BR112019024851A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Abstract

a presente invenção refere-se a um fármaco que evita o progresso de doença de alzheimer e um método para evitar progresso de doença de alzheimer. 1-(3-(2-(1-benzotiofen-5-il)etóxi)propil)azetidin-3-ol ou um sal do mesmo tem um efeito de suprimir atrofia cerebral e é útil como um agente para evitar ou tratar atrofia cerebral. a atrofia cerebral observada em envelhecimento ou doenças neurodegenerativas pode ser evitada ou tratada por administrar 1-(3-(2-(1-benzotiofen-5-il)etóxi)propil)azetidin-3-ol ou um sal do mesmo.
BR112019024851A 2017-06-02 2018-06-01 agente para evitar ou tratar atrofia cerebral BR112019024851A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2017109885 2017-06-02
JP2017128472 2017-06-30
JP2017145100 2017-07-27
PCT/JP2018/021223 WO2018221729A1 (ja) 2017-06-02 2018-06-01 脳萎縮予防または治療剤

Publications (1)

Publication Number Publication Date
BR112019024851A2 true BR112019024851A2 (pt) 2020-06-09

Family

ID=64455855

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019024851A BR112019024851A2 (pt) 2017-06-02 2018-06-01 agente para evitar ou tratar atrofia cerebral

Country Status (15)

Country Link
US (1) US11951092B2 (pt)
EP (1) EP3632431A4 (pt)
JP (2) JP7282028B2 (pt)
KR (1) KR20190137936A (pt)
CN (3) CN116492335A (pt)
AU (1) AU2018276638B2 (pt)
BR (1) BR112019024851A2 (pt)
CA (1) CA3067453C (pt)
IL (1) IL270922A (pt)
MX (1) MX2019014310A (pt)
NZ (1) NZ759585A (pt)
RU (1) RU2759727C2 (pt)
SG (1) SG11201911512SA (pt)
WO (1) WO2018221729A1 (pt)
ZA (1) ZA201907973B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116492335A (zh) * 2017-06-02 2023-07-28 富士胶片富山化学株式会社 脑萎缩预防或治疗剂
IL270910B2 (en) 2017-06-02 2024-03-01 Fujifilm Toyama Chemical Co Ltd 1-(3-(2-(1-benzothiophene-5-yl)ethoxy)propyl)aztidine-3-ol or a salt thereof for use in suppressing cerebral atrophy
WO2018221728A1 (ja) 2017-06-02 2018-12-06 富山化学工業株式会社 アルツハイマー型認知症予防または治療剤
JP7256118B2 (ja) 2017-06-02 2023-04-11 富士フイルム富山化学株式会社 アミロイドβ蛋白質量減少剤
JP7227914B2 (ja) 2017-10-30 2023-02-22 富士フイルム富山化学株式会社 エモパミル結合タンパク質結合剤およびその利用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001514024A (ja) 1997-09-05 2001-09-11 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ５０個のヒト分泌タンパク質
GB9824207D0 (en) 1998-11-04 1998-12-30 Zeneca Ltd Neurological disorders
KR100956990B1 (ko) 2001-10-19 2010-05-11 토야마 케미칼 컴퍼니 리미티드 알킬에테르유도체 또는 그 염
ES2379948T3 (es) * 2002-06-14 2012-05-07 Toyama Chemical Co., Ltd. Composición medicinal que comprende Tacrine o Donepezil para mejorar la función cerebral
MXPA05011125A (es) 2003-04-17 2005-12-14 Toyama Chemical Co Ltd Remedio preventivo para enfermedades del nervio retiniano que contienen derivados de eter de alquilo o sales de los mismos.
PL2011796T3 (pl) * 2006-04-26 2015-03-31 Toyama Chemical Co Ltd Induktor neurogenezy lub środek terapeutyczny do stosowania w neuropatii zawierający pochodną eteru alkilowego lub jej sól
US8119625B2 (en) * 2006-04-26 2012-02-21 Toyama Chemical Co., Ltd. Neurogenesis inducer or neuropathy therapeutic agent comprising alkyl ether derivative or salt thereof
EA017842B1 (ru) 2008-03-04 2013-03-29 Вернэлис (Р&Д) Лтд. Производные азетидина и их применение
FR2934596B1 (fr) 2008-07-30 2015-04-10 Trophos Nouveaux derives de l'oxime de cholest-4-en-3-one, compositions pharmaceutiques les renfermant, et procede de preparation
JP2012523437A (ja) 2009-04-13 2012-10-04 セラヴァンス， インコーポレーテッド 認知障害の治療のための５−ｈｔ４受容体アゴニスト化合物
JP5808319B2 (ja) 2009-05-11 2015-11-10 フォルム ファーマシューティカルズ、インコーポレイテッド アセチルコリンエステラーゼ阻害剤と組み合わせた特定のα７ニコチン酸受容体を用いた認知障害の治療
WO2011057199A1 (en) 2009-11-06 2011-05-12 Adenios, Inc. Compositions for treating cns disorders
US9872914B2 (en) 2012-02-22 2018-01-23 Toyama Chemical Co., Ltd. Solid pharmaceutical composition containing 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or salt thereof
JP6397407B2 (ja) 2012-07-19 2018-09-26 ドレクセル ユニバーシティ 細胞タンパク質ホメオスタシスを調節するためのシグマ受容体リガンド
EP2903980B1 (en) 2012-10-01 2017-07-19 F. Hoffmann-La Roche AG Benzimidazoles as cns active agents
EP3100725B1 (en) * 2014-01-31 2020-05-06 FUJIFILM Toyama Chemical Co., Ltd. Post nerve injury rehabilitation effect-enhancing agent comprising an alkyl ether derivative or a salt thereof
WO2015163318A1 (ja) 2014-04-25 2015-10-29 レジリオ株式会社 アルツハイマー病の治療剤を含む、神経細胞の軸索の機能不全が関与する疾患の治療剤
WO2015188368A1 (en) 2014-06-13 2015-12-17 Merck Sharp & Dohme Corp. Pyrrolo[2,3-c]pyridines as imaging agents for neurofibrilary tangles
WO2016051799A1 (ja) 2014-10-01 2016-04-07 学校法人同志社 ２－アミノヒドロキノン誘導体及びタウ凝集阻害剤
MY191590A (en) 2015-02-02 2022-06-30 Ucb Biopharma Sprl 9h-pyrrolo-dipyridine derivatives
US20160324851A1 (en) 2015-05-07 2016-11-10 Axovant Sciences, Ltd. Methods of treating a neurodegenerative disease
JP6761413B2 (ja) 2015-06-11 2020-09-23 富士フイルム富山化学株式会社 シグマ受容体結合剤
US11304928B2 (en) 2015-12-25 2022-04-19 Fujifilm Toyama Chemical Co., Ltd. Tablet comprising 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or salt thereof
CN116492335A (zh) * 2017-06-02 2023-07-28 富士胶片富山化学株式会社 脑萎缩预防或治疗剂
IL270910B2 (en) 2017-06-02 2024-03-01 Fujifilm Toyama Chemical Co Ltd 1-(3-(2-(1-benzothiophene-5-yl)ethoxy)propyl)aztidine-3-ol or a salt thereof for use in suppressing cerebral atrophy
WO2018221728A1 (ja) 2017-06-02 2018-12-06 富山化学工業株式会社 アルツハイマー型認知症予防または治療剤
EP3636261A4 (en) 2017-06-02 2020-06-10 FUJIFILM Toyama Chemical Co., Ltd. AGENT FOR PREVENTING OR TREATING TAUOPATHY
JP7256118B2 (ja) 2017-06-02 2023-04-11 富士フイルム富山化学株式会社 アミロイドβ蛋白質量減少剤
JP7227914B2 (ja) 2017-10-30 2023-02-22 富士フイルム富山化学株式会社 エモパミル結合タンパク質結合剤およびその利用

Also Published As

Publication number Publication date
SG11201911512SA (en) 2020-01-30
RU2019138166A3 (pt) 2021-07-09
KR20190137936A (ko) 2019-12-11
AU2018276638A1 (en) 2019-12-19
EP3632431A1 (en) 2020-04-08
CA3067453C (en) 2021-11-23
US20200215030A1 (en) 2020-07-09
EP3632431A4 (en) 2020-06-03
MX2019014310A (es) 2022-06-10
RU2019138166A (ru) 2021-07-09
ZA201907973B (en) 2022-03-30
IL270922A (en) 2020-01-30
WO2018221729A1 (ja) 2018-12-06
NZ759585A (en) 2022-02-25
CA3067453A1 (en) 2018-12-06
US11951092B2 (en) 2024-04-09
JPWO2018221729A1 (ja) 2020-04-09
CN116473962A (zh) 2023-07-25
RU2759727C2 (ru) 2021-11-17
JP7282028B2 (ja) 2023-05-26
CN110709078A (zh) 2020-01-17
AU2018276638B2 (en) 2021-04-08
CN116492335A (zh) 2023-07-28
JP2023053337A (ja) 2023-04-12

Similar Documents

Publication Publication Date Title
BR112019024851A2 (pt) agente para evitar ou tratar atrofia cerebral
BR112019024878A2 (pt) Agente para prevenção ou tratamento de tauopatia
BR112017003546A2 (pt) amidas heterocíclicas como inibidores de rip1 quinase como medicamentos
MX2016014634A (es) Compuestos para el tratamiento de enfermedades y trastornos oftalmicos.
BR112017008093A2 (pt) processos para tratamento de doenças oculares
BR112017017078A2 (pt) composto, composição farmacêutica, uso de um composto, e, método para prevenir, gerenciar, tratar ou amenizar uma doença.
MX2009011127A (es) Metodo de prevencion y tratamiento de angiopatia amiloide cerebral.
MX2019007586A (es) Composiciones que comprenden tacrolimus para el tratamiento de enfermedades inflamatorias intraoculares.
CR20120638A (es) Métodos de terapia combinada para tratar enfermedades proliferativas
BR112017028132A2 (pt) métodos de tratamento de malignidade hematológica usando terapia combinada de inibidor de mtor em nanopartícula
MX2022010274A (es) Uso de dexmedetomidina sublingual para el tratamiento de la agitacion.
BR112015024530A2 (pt) composto, métodos para tratamentos de distúrbios e de doenças e para profilaxia de distúrbios, composição farmacêutica, e, uso de um composto
MX2017010982A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
BR112019024881A2 (pt) Agente para evitar ou tratar ataxia espinocerebelar
MX2014002459A (es) Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodos de uso de los mismos.
BR112015018438A2 (pt) anticorpo contra c5 e método para prevenir e tratar doenças relacionadas a complemento
AR101740A1 (es) Terapia de combinación y composiciones
PH12017502049A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
MX2014001088A (es) Ciertos inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas, y metodos de uso de las mismas.
BR112015011213A2 (pt) Composto, composição farmacêutica, método de prevenção ou tratamento de um distúrbio ou doença de controle respiratório em um indivíduo, método de prevenção de desestabilização ou de estabilização do ritmo respiratório em um indivíduo, método de preparação de o,n-dimetil-n-[4-(n-propilamina)-6-(prop-2-inilamina)-[1,3,5]triazin-2-il]-hidroxilamina, e composição.
BR112015021334A2 (pt) formulações oculares para entrega de droga ao segmento posterior do olho
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
BR112019004684A2 (pt) combinação de agonistas de fxr
BR112017013674A2 (pt) métodos e composições para tratamento de doenças cerebrais.
BR112015020963A2 (pt) derivado de 2-acilaminotiazola ou sal do mesmo

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]